WordNet

the 12th letter of the Roman alphabet (同)l

PrepTutorEJDIC

lira(イタリアの貨幣単位リラ)
low frequency

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/12/10 15:31:08」(JST)

wiki en

CD58, or lymphocyte function-associated antigen 3 (LFA-3), is a cell adhesion molecule expressed on Antigen Presenting Cells (APC), particularly macrophages.^[1]^[2]

It binds to CD2 (LFA-2) ^[3] ^[4] on T cells and is important in strengthening the adhesion between the T cells and Professional Antigen Presenting Cells. This adhesion occurs as part of the transitory initial encounters between T cells and Antigen Presenting Cells before T cell activation, when T cells are roaming the lymph nodes looking at the surface of APCs for peptide:MHC complexes the T-cell receptors are reactive to.

Polymorphisms in the CD58 gene are associated with increased risk for multiple sclerosis.^[5]

References

^ Barbosa JA, Mentzer SJ, Kamarck ME, Hart J, Biro PA, Strominger JL, Burakoff SJ (April 1986). "Gene mapping and somatic cell hybrid analysis of the role of human lymphocyte function-associated antigen-3 (LFA-3) in CTL-target cell interactions". J. Immunol. 136 (8): 3085–91. PMID 3514752.
^ Wallich R, Brenner C, Brand Y, Roux M, Reister M, Meuer S (15 March 1998). "Gene structure, promoter characterization, and basis for alternative mRNA splicing of the human CD58 gene". J. Immunol. 160 (6): 2862–71. PMID 9510189.
^ Selvaraj P, Plunkett ML, Dustin M, Sanders ME, Shaw S, Springer TA (1987). "The T lymphocyte glycoprotein CD2 binds the cell surface ligand LFA-3". Nature 326 (6111): 400–3. doi:10.1038/326400a0. PMID 2951597.
^ Wang JH, Smolyar A, Tan K, Liu JH, Kim M, Sun ZY, Wagner G, Reinherz EL (June 1999). "Structure of a heterophilic adhesion complex between the human CD2 and CD58 (LFA-3) counterreceptors". Cell 97 (6): 791–803. doi:10.1016/S0092-8674(00)80790-4. PMID 10380930.
^ De Jager PL, Baecher-Allan C, Maier LM, Arthur AT, Ottoboni L, Barcellos L, McCauley JL, Sawcer S, Goris A, Saarela J, Yelensky R, Price A, Leppa V, Patterson N, de Bakker PI, Tran D, Aubin C, Pobywajlo S, Rossin E, Hu X, Ashley CW, Choy E, Rioux JD, Pericak-Vance MA, Ivinson A, Booth DR, Stewart GJ, Palotie A, Peltonen L, Dubois B, Haines JL, Weiner HL, Compston A, Hauser SL, Daly MJ, Reich D, Oksenberg JR, Hafler DA. (9 June 2009). "The role of the CD58 locus in multiple sclerosis". Proc Natl Acad Sci U S A. 106 (13): 5264–9. doi:10.1073/pnas.0813310106. PMC 2664005. PMID 19237575.

External links

CD58 Antigen at the US National Library of Medicine Medical Subject Headings (MeSH)

This biochemistry article is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. NK細胞欠損症候群：臨床症状および診断 nk cell deficiency syndromes clinical manifestations and diagnosis
2. エプスタインバーウイルス（EBウイルス）感染の臨床的特徴および治療 clinical manifestations and treatment of epstein barr virus infection
3. 臨床的腎移植における研究中の免疫抑制剤およびそのアプローチ investigational immunosuppressive drugs and approaches in clinical kidney transplantation
4. 造血細胞移植後の移植片対腫瘍効果の生物学 biology of the graft versus tumor effect following hematopoietic cell transplantation
5. 胎児および新生児における免疫細胞の発達 the development of immune cells in the fetus and neonate

English Journal

Results of a Randomized Phase I Gene Therapy Clinical Trial of Non-oncolytic Fowlpox Viruses Encoding T cell Co-stimulatory Molecules.

Kaufman HL, Kim DW, Kim-Schulze S, Deraffele G, Joagoda MC, Broucek J, Zloza A.Author information Rutgers University, Surgery, 195 Little Albany Street, New Brunswick, New Jersey, United States, 08901, 917-822-7778, 732-235-6797 ; howardkaufman6@gmail.com.AbstractOncolytic viruses have shown promise as gene delivery vehicles in the treatment of cancer; however, their efficacy may be inhibited by the induction of anti-viral antibody titers. Fowlpox virus is a non-replicating and non-oncolytic vector that has been associated with lesser humoral but greater cell-mediated immunity in animal tumor models. To test whether fowlpox virus gene therapy is safe and can elicit immune responses in cancer patients, we conducted a randomized phase I clinical trial of two recombinant fowlpox viruses encoding human B7.1 or a triad of co-stimulatory molecules (B7.1, ICAM-1, and LFA-3; TRICOM). Twelve patients (10 melanoma and two colon adenocarcinoma) enrolled in the trial and were randomized to rF-B7.1 or rF-TRICOM administered in a dose escalation manner (~3.7 x 107 or ~3.7 x 108 PFU) by intra-lesional injection every four weeks. The therapy was well tolerated with only four patients experiencing grade 1 fever or injection site pain and there were no serious adverse events. All patients developed anti-viral antibody titers following vector delivery and post-treatment anti-CEA antibody titers were detected in the two patients with colon cancer. All patients developed CD8+ T cell responses against fowlpox virus but few responses against defined tumor-associated antigens were observed. To our knowledge, this is the first clinical trial of direct (intra-tumoral) gene therapy with a non-oncolytic fowlpox virus. Treatment was well tolerated in patients with metastatic cancer and all subjects exhibited anti-viral antibody responses but limited tumor-specific T cell responses were detected. Non-oncolytic fowlpox viruses are safe and induce limited T cell responses in cancer patients. Further development may include prime-boost strategies utilizing oncolytic viruses for initial priming.
Human gene therapy.Hum Gene Ther.2014 Feb 2. [Epub ahead of print]
Oncolytic viruses have shown promise as gene delivery vehicles in the treatment of cancer; however, their efficacy may be inhibited by the induction of anti-viral antibody titers. Fowlpox virus is a non-replicating and non-oncolytic vector that has been associated with lesser humoral but greater cel
PMID 24484178

Increased numbers and functional activity of CD56+ T cells in healthy cytomegalovirus positive subjects.

Almehmadi M, Flanagan BF, Khan N, Alomar S, Christmas SE.Author information Department of Clinical Infection, Microbiology and Immunology, Institute of Infection & Global Health, University of Liverpool, Liverpool, UK.AbstractHuman T cells expressing CD56 are capable of tumour cell lysis following activation with IL-2 but their role in viral immunity has been less well studied. Proportions of CD56+ T cells were found to be highly significantly increased in CMV seropositive (CMV+) compared to seronegative (CMV-) healthy subjects (9.1±1.5% vs. 3.7±1.0%; p<0.0001). Proportions of CD56+ T cells expressing CD28, CD62L, CD127, CD161 and CCR7 were significantly lower in CMV+ than CMV- subjects but that those expressing CD4, CD8, CD45RO, CD57, CD58, CD94 and NKG2C were significantly increased (p<0.05), some having the phenotype of TEM cells. Levels of proinflammatory cytokines and CD107a were significantly higher in CD56+ T cells from CMV+ than CMV- subjects following stimulation with CMV antigens. This also resulted in higher levels of proliferation in CD56+ T cells from CMV+ than CMV- subjects. Using Class I HLA pentamers, it was found that CD56+ T cells from CMV+ subjects contained similar proportions of antigen-specific CD8+ T cells to CD56- T cells in donors of several different HLA types. These differences may reflect expansion and enhanced functional activity of CMV-specific CD56+ memory T cells. In view of the link between CD56 expression and T cell cytotoxic function, this strongly implicates CD56+ T cells as being an important component of the cytotoxic T cell response to CMV in healthy carriers. This article is protected by copyright. All rights reserved.
Immunology.Immunology.2014 Jan 16. doi: 10.1111/imm.12250. [Epub ahead of print]
Human T cells expressing CD56 are capable of tumour cell lysis following activation with IL-2 but their role in viral immunity has been less well studied. Proportions of CD56+ T cells were found to be highly significantly increased in CMV seropositive (CMV+) compared to seronegative (CMV-) healthy s
PMID 24433347

Japanese Journal

次世代の生物学的製剤(第10回)アレファセプト

梅原久範
分子リウマチ治療 3(3), 144-148, 2010-08-00
NAID 40017238659

Preparation of a Lemon Flavonoid Aglycone and its Suppressive Effect on the Susceptibility of LDL to Oxidation Following Human Ingestion

MIYAKE Yoshiaki,SAKURAI Chika,USUDA Mika,HIRAMITSU Masanori,KONDO Kazuo
Food science and technology research 15(1), 83-88, 2009-01-01
… It is indicated to have low bioavailability compared with lemon flavonoid aglycone (LFA), which predominantly contains eriodictyol. … This study attempted to prepare LFA which has high bioavailability, using enzymes that are commonly used in the citrus industry, such as cellulase, naringinase, hesperidinase, and pectinase. … LFA containing the highest amount of eriodictyol (19.4%) was prepared with naringinase, a debittering enzyme for citrus juice. …
NAID 10025348617

Enhanced Fc-Dependent Cellular Cytotoxicity of Fc Fusion Proteins Derived from TNF Receptor II and LFA-3 by Fucose Removal from Asn-Linked Oligosaccharides

Shoji-Hosaka Emi,Kobayashi Yukari,Wakitani Masako [他],UCHIDA Kazuhisa,NIWA Rinpei,NAKAMURA Kazuyasu,SHITARA Kenya
The journal of biochemistry 140(6), 777-783, 2006-12-01
NAID 10018840363

Related Pictures

★リンクテーブル★

リンク元	「接着分子」「T細胞」「CD2」「CD58」
関連記事	「LF」「L」「LFA」

「接着分子」

CD58 molecule
Identifiers
Symbol	CD58
Alt. symbols	LFA3
Entrez	965
HUGO	1688
OMIM	153420
RefSeq	NM_001779
UniProt	P19256
Other data
Locus	Chr. 1 p13

　　[★]

英: adhesion molecule
同: 接着因子
関

接着分子のファミリー

インテグリンファミリー
Igスーパーファミリー
セレクチンファミリー
CD44ファミリー
カドヘリンファミリー

白血球の相互作用に関与している接着分子 (IMM.87)

グループ名	機能	名称	別名		組織分布	リガンド
セレクチン	炭化水素鎖に結合。白血球-内皮細胞の反応を開始	P-selectin	PADGEN	CD62P	活性化した内皮細胞、活性化した血小板	PSGL-1, sialyl-Lewisx
セレクチン	炭化水素鎖に結合。白血球-内皮細胞の反応を開始	E-selectin	ELAM-1	CD62E	活性化した内皮細胞	sialyl-Lewisx
インテグリン	CAMや細胞外マトリックスに結合。強い結合	LFA-1	αL:β2	CD11a:CD18	単球、T細胞、マクロファージ、好中球、樹状細胞	ICAMs
		CR3, Mac-1	αM:β2	CD11b:CD18	好中球、単球、マクロファージ	ICAM-1, iC3b, fibrinogen
		CR4, p150.95	αX:β2	CD11c:CD18	樹状細胞、マクロファージ、好中球	iC3b
		VLA-5	α5:β1	CD49d:CD29	単球、マクロファージ	fibronectin
免疫グロブリンスーパーファミリー	細胞結合で様々に働く。インテグリンの基質	ICAM-1		CD54	活性化した内皮細胞	LFA-1, MAC1
		ICAM-2		CD102	非活性化状態の内皮細胞、樹状細胞	LFA-1
		VCAM-1		CD106	活性化した内皮細胞	VLA-4
		PECAM		CD31	活性化した白血球、内皮細胞間の結合	CD31

白血球の相互作用に関与している免疫グロブリンスーパーファミリーの接着分子 (IMM.329)

名称		分布組織	リガンド
CD2	LFA-2	T細胞	LFA-1	CD53
ICAM-1	CD54	活性化した血管、リンパ球、樹状細胞	LFA-1, Mac-1
ICAM-2	CD102	非活性化状態の血管	LFA-1
ICAM-3	CD50	Naive T cells	DC-SIGN, LFA-1
LFA-3	CD58	リンパ球、APC	CD2
VCAM-1	CD106	活性化した内皮細胞	VLA-4

-接着分子

-細胞接着分子

-カドヘリン

「T細胞」

　　[★]

英: T cell
同: Tリンパ球、T lymphocyte
関: TCR、B細胞、MHC

図：IMM.315(T細胞の成熟)
胸腺で成熟したT細胞は血流によって移動し、リンパ節の傍皮質、白脾髄のリンパ性動脈周囲鞘、パイエル板の傍濾胞域に集まる(人間の正常構造と機能 VIIA血管・免疫 p.28)

種類

T細胞の抗原認識 (SP.248)

	CD	TCRが抗原と共に認識する分子	認識する細胞
Tc細胞	CD8	MHCクラスI	感染細胞
Th細胞	CD4	MHCクラスII	抗原提示細胞

CD4+ T細胞のサイトカイン放出とその原因

DCが認識する外来異物	DCが分泌する物質	DCに反応する細胞	この細胞が分泌するサイトカイン	NK系の細胞が放出したサイトカインに反応するTh細胞	Th細胞が分泌するサイトカイン
ウイルス、一部の細菌	IL-12	NK細胞(IL-12による)	INF-γ	Th1	IL-2, IFN-γ, TNF-β
原虫など		NKT細胞	IL-4	Th2	IL-4, IL-13, IL-5

Th細胞活性化と接着分子

	抗原提示細胞	Th細胞
主シグナル	MHC classII	TCR, CD3
主シグナル	MHC classII	CD4
副シグナル	B7{B7-1(CD80)/B7-2(CD86)}	CD28
	VCAM-1(CD106)	VLA-4
	ICAM-1	LFA-1
	LFA-3(CD58)	CD2